<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045526</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01418</org_study_id>
    <secondary_id>02-035</secondary_id>
    <secondary_id>NSC-718781</secondary_id>
    <secondary_id>NCI-5445</secondary_id>
    <secondary_id>CDR0000256601</secondary_id>
    <secondary_id>MSKCC-02035</secondary_id>
    <secondary_id>N01CM62206</secondary_id>
    <nct_id>NCT00045526</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer</brief_title>
  <official_title>Phase II Study Of OSI-774 In Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying erlotinib hydrochloride to see how well it works in treating&#xD;
      patients with advanced esophageal cancer or stomach cancer. Erlotinib hydrochloride may stop&#xD;
      the growth of cancer by blocking the enzymes necessary for tumor cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the objective response rate in patients with advanced carcinoma of the esophagus&#xD;
      or gastroesophageal junction treated with erlotinib (erlotinib hydrochloride).&#xD;
&#xD;
      II. Determine the overall survival of patients treated with this drug. III. Determine the&#xD;
      degree of dysphagia relief in patients treated with this drug.&#xD;
&#xD;
      IV. Determine the toxicity and tolerability of this drug in these patients. V. Correlate&#xD;
      epidermal growth factor receptor (EGFR) expression with response to treatment in these&#xD;
      patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive erlotinib hydrochloride orally (PO) once daily (QD). Courses repeat every 4&#xD;
      weeks in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major response rate (complete and partial response)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities, graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of dysphagia relief</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Estimated using the Kaplan-Meier method and confidence intervals will be formed for median time to progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Estimated using the Kaplan-Meier method and confidence intervals will be formed for median survival time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Adenocarcinoma of the Esophagus</condition>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <condition>Recurrent Esophageal Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Esophagus</condition>
  <condition>Stage III Esophageal Cancer</condition>
  <condition>Stage IV Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma, squamous cell or small cell&#xD;
             carcinoma, or carcinoma not otherwise specified of the esophagus or gastroesophageal&#xD;
             junction&#xD;
&#xD;
               -  Metastatic or surgically unresectable disease&#xD;
&#xD;
          -  Measurable disease outside of primary tumor&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral computed&#xD;
                  tomography (CT) scan&#xD;
&#xD;
          -  No bone metastases, abnormal radionuclide bone scans, or pleural effusions as only&#xD;
             site of measurable disease&#xD;
&#xD;
          -  No known brain metastases or carcinomatous meningitis&#xD;
&#xD;
          -  Must consent to having tumor tissue tested for epidermal growth factor receptor status&#xD;
&#xD;
          -  Performance status-Karnofsky 70-100%&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) no greater than 2 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Calcium no greater than 12 mg/dL&#xD;
&#xD;
          -  No symptomatic hypercalcemia&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No ventricular arrhythmia&#xD;
&#xD;
          -  No other malignancy within the past 3 years except adequately treated carcinoma in&#xD;
             situ of the cervix, superficial transitional cell carcinoma of the bladder, or basal&#xD;
             cell or squamous cell skin cancer&#xD;
&#xD;
          -  No other uncontrolled concurrent illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No other concurrent disease that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior cetuximab&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for advanced or metastatic disease&#xD;
&#xD;
          -  One prior chemotherapy in the adjuvant setting (in combination with prior surgery or&#xD;
             radiotherapy) allowed provided it was administered prior to treatment for advanced or&#xD;
             metastatic disease&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent investigational or commercial chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior erlotinib-related compounds or compounds of similar biologic or chemical&#xD;
             components&#xD;
&#xD;
          -  No prior EGFR-targeting compounds (e.g., gefitinib)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for human immunodeficiency virus&#xD;
             (HIV)-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ilson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

